Board changes put Inspire Medical Systems in focus

Inspire Medical Systems (INSP) is drawing attention after two recent board moves: the appointment of Michael H. Carrel as a Class III director and the upcoming retirement of long-serving director Casey M. Tansey.

Despite the boardroom changes, Inspire Medical Systems’ share price tells a mixed story, with a 30 day share price return of 13.87%, a year to date share price decline of 46.69%, and a 1 year total shareholder return decline of 61.83%. This suggests that recent momentum is recovering from a much weaker longer term trend.

If this kind of healthcare re rating has your attention, it could be a good moment to broaden your search using our screener of 39 healthcare AI stocks.

After Inspire Medical Systems' sharp share price swings, the stock now sits at a modest discount to both analyst targets and estimated fair value. So is the market prudently cautious or too reluctant to re rate the story yet again?

Most Popular Narrative: 5.7% Undervalued

Inspire Medical Systems last closed at $49.19, slightly below the most followed fair value estimate of $52.17. This estimate hinges on detailed long term revenue and earnings assumptions under a specific discount rate of 7.59%.

The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues. As these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent up demand is realized.

Want to see what sits behind that fair value for Inspire Medical Systems? Revenue growth assumptions, thinner margins, and a higher future earnings multiple all pull in different directions. The narrative ties them together in a single forward path and leaves one key variable doing most of the heavy lifting.

Result: Fair Value of $52.17 (UNDERVALUED)

However, investors in Inspire Medical Systems still need to weigh coding uncertainty around Inspire V, as well as the heavy reliance on one primary product, which could disrupt this narrative.

Next Steps

With Inspire Medical Systems’ story carrying both clear risks and genuine bright spots, this is a good time to look at the numbers yourself and decide where you stand. You can then weigh up the balance by checking the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Inspire Medical Systems?

If Inspire Medical Systems has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target potential mispricing by scanning companies that combine quality fundamentals with room for sentiment to shift using our 49 high quality undervalued stocks.
• Prioritise resilience first and seek companies with sturdier balance sheets and healthier fundamentals through the solid balance sheet and fundamentals stocks screener (49 results).
• Hunt for lesser known prospects that still clear high quality hurdles with the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.